Background: Mucormycosis has emerged as an epidemic within the COVID-19 pandemic due to widespread use of corticosteroids and immune-modulators like Tocilizumab, in the management of COVID-19 pneumonia,. It is an invasive fungal disease which spreads by angioinvasion and rapidly spreads to adjacent tissues. If untreated its outcomes are dangerous and often fatal. Uncontrolled diabetes, malignancies and dialysis are predisposing factors. Raised blood iron is an important factor in pathogenesis and rapid progression of fungal invasion that needs to be investigated. Aim: To establish a correlation between raised serum ferritin level and aggressiveness of Mucormycosis. Methodology: A retrospective study was done from February 2021 to February 2022 of patients diagnosed with mucormycosis by middle meatal biopsy and microscopy along with CT & MRI scan of PNS with brain. They were treated either surgically or conservatively. All the blood parameters including serum ferritin level, were carried out. A comparison was done on extent of disease in patients in-relation to their serum ferritin level. Results: Our study suggested that higher levels of ferritin are often associated with aggressive form the disease. Zygomycetes are dependent on environmental iron for their growth. Higher the serum ferritin level, more aggressive & widespread is mucormycosis. Conclusion: Serum free iron aggravates mucormycosis. Measures should take to control the serum ferritin in patients under risk for mucormycosis. Iron chelating agents or novel methods like anti-ftr1 immune serum should be developed for controlling the disease at its earlier stages.
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An update. J Fungi (Basel). 2020;6(4). Doi:10.3390/jof6040265. pmid:33147877
Paltauf, A. Mycosis mucorina: Ein Beitrag zur Kenntnis der menschilchen Fadenpiltzer-krankungen. Virchows Arch. Pathol. Anat. 1885, 102, 543–564. [CrossRef]
Fürbringer, P. Beobachtungen über Lungenmycose beim Menschen. Virchows Arch. 1876, 66, 330–365.[CrossRef]
Chander, J.; Singla, N.; Kaur, M.; Punia, R.S.; Attri, A.; Alastruey-Izquierdo, A.; Stchigel, A.M.; Cano-Lira, J.F.; Guarro, J. Saksenaea erythrospora, an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections—A study from a tertiary care hospital in north India. Infect. Dis. 2017, 49, 170–177.[CrossRef]
Patel A, Agarwal R, Rudramurthy S.M. Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India. CDC. Early release. Emerging Infectious Diseases. Disponible en: https://wwwnc.cdc.gov/eid/article/27/9/21-0934_article#suggestedcitation
Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Elsevier, 2005: 2979.
Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74:150–60.
Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser 1989; 47:243–71.
Diamond RD, Haudenschild CC, Erickson NF 3rd. Monocyte-mediated damage to Rhizopus arrhizus hyphae in vitro. Infect Immun 1982; 38:292–7.
Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus arrhizus in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38:1123–9.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1(Suppl 1):S16-S22. doi:10.1093/cid/cir865
Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008; 21:620–5.
Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31:1109–14.
Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest 1993; 91:1979–86.
Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006; 58:1070–3.
Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117:2649–57.
Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18:660–7.
Boelaert JR, Fenves AZ, Coburn JW. Registry on mucormycosis in dialysis patients. J Infect Dis 1989; 160:914.
Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24:307–12.
Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev 1999; 12:394–404.
Stearman R, Yuan DS, Yamaguchi-Iwai Y, Klausner RD, Dancis A. A permease-oxidase complex involved in high-affinity iron uptake in yeast. Science 1996; 271:1552–7.
Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus arrhizus reveals a whole-genome duplication. PLoS Genet 2009; 5:e1000549.
Ibrahim AS, Gebremariam T, Lin L, et al. The high affinity iron permease is a key virulence factor required for Rhizopus arrhizus pathogenesis. Mol Microbiol 2010; 77:587–604.
Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus arrhizus adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005; 73:778–83.
Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J ClinnInvest 2010; 120:1914–24.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–21.
Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, et al. ECMM/ISHAM recommendations for clinical management of COVID -19 associated
mucormycosis in low- and middle-income countries. Mycoses. 2021. doi:10.1111/myc.13335. pmid:34133816
Sipsas, N.V.; Gamaletsou, M.N.; Anastasopoulou, A.; Kontoyiannis, D.P. Therapy of Mucormycosis. J. Fungi 2018, 4, 90. [CrossRef]
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2022 Dr. Sandeep Chahande, Dr. Gajanan M. Kashid , Dr. Ashok Gaikwad, Dr. Abhijit Futane, Dr. Siddharth A. Purohit , Dr. Shamal K. Waghmare , Dr. Harshala Palwe